Article
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
The Lancet. Haematology - 1 Apr 2020
Stein Eytan M, Fathi Amir T, DiNardo Courtney D, Pollyea Daniel A, Roboz Gail J, Collins Robert, Sekeres Mikkael A, Stone Richard M, Attar Eyal C, Frattini Mark G, Tosolini Alessandra, Xu Qiang, See Wendy L, MacBeth Kyle J, de Botton Stéphane, Tallman Martin S, Kantarjian Hagop M
Abstract excerpt
BACKGROUND: Mutations in isocitrate dehydrogenase-2 (IDH2) occur in around 5% of patients with myelodysplastic syndromes. Neomorphic activity of mutant IDH2 proteins results in hypermethylation of DNA and histones, leading to blocked haemopoietic differentiation. Enasidenib, an inhibitor of mutated IDH2 proteins, induces responses in patients with IDH2-mutated, relapsed or refractory acute myeloid leukaemia. We...
Topics
Join the communities discussing this publication.